The International Pediatric Adrenocortical Tumor Registry initiative: Contributions to clinical, biological, and treatment advances in pediatric adrenocortical tumors

Molecular and Cellular Endocrinology

Volumn 351, Issue 1, 2012, Pages 37-43

  Ribeiro, Raul C ^a   Pinto, Emilia M ^a   Zambetti, Gerard P ^a   Rodriguez Galindo, Carlos ^b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Adrenocortical tumor; Arg337His; Pediatric Adrenocortical Tumor Registry; Rare disease; TP53 mutation

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; MITOTANE;

ADRENAL CORTEX CARCINOMA; CANCER PROGNOSIS; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); CUSHING SYNDROME; DATA ANALYSIS; DIARRHEA; EVENT FREE SURVIVAL; HETEROZYGOSITY; HISTORY OF MEDICINE; HUMAN; MEDICAL RESEARCH; MUTATIONAL ANALYSIS; NAUSEA; NEUROTOXICITY; OUTCOME ASSESSMENT; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PROGNOSIS; RARE DISEASE; REVIEW; SURVIVAL TIME; TUMOR SUPPRESSOR GENE; VIRILIZATION; VOMITING;

ADOLESCENT; ADRENOCORTICAL CARCINOMA; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; REGISTRIES;

EID: 84857122951     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.10.015     Document Type: Review

References (58)

1. Altekruse SF et al., 2010. SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD. Available from: <>, based on November 2009 SEER data submission, posted to the SEER web site). http://seer.cancer.gov/csr/1975_2007/.
2. Allolio B., Fassnacht M. Adrenocortical carcinoma: clinical update. J. Endocrinol. Metab. 2006, 91:2027-2037.
3. Assumpcao J.G., Seidinger A.L., Mastellaro M.J., Ribeiro R.C., Zambetti G.P., Ganti R., et al. Association of the germline TP53 R337H mutation with breast cancer in southern Brazil. BMC cancer 2008, 8:357.
4. Bugg M.F., Ribeiro R.C., Roberson P.K., Lloyd R.V., Sandrini R., Silva J.B., et al. Correlation of pathologic features with clinical outcome in pediatric adrenocortical neoplasia. A study of a Brazilian population. Brazilian group for treatment of childhood adrenocortical tumors. Am. J. Clin. Pathol. 1994, 101:625-629.
5. Coleman, M.P. et al., 1999. Cancer Survival Trends in England and Wales, 1971-1995: Deprivation and NHS Region. The Stationery Office, London.
6. Crucitti F., Bellantone R., Ferrante A., Boscherini M., Crucitti P. The Italian registry for adrenal cortical carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian registry study group. Surgery 1996, 119:161-170.
7. Custodio, G., 2011. Neonatal Screening for R337H TP53 mutation, Early Diagnosis of Childhood Adrenocortical Carcinoma and History of Cancer in Families from Parana State. Thesis, Federal University of Paraná, Brazil (in Portuguese).
8. Custodio G., Taques G.R., Figueiredo B.C., Gugelmin E.S., Oliveira Figueiredo M.M., Watanabe F., et al. Increased incidence of choroid plexus carcinoma due to the germline TP53 R337H mutation in southern Brazil. PLoS ONE 2011, 6:e18015.
9. De Leon D.D., Lange B.J., Walterhouse D., Moshang T. Long-term (15 Years) outcome in an infant with metastatic adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 2002, 87:4452-4456.
10. Dehner L.P. Neoplasms of the adrenal cortex. Preoccupation bordering on obsession. Am. J. Clin. Pathol. 1994, 101:557-558.
11. Dyer M.A., Rodriguez-Galindo C., Wilson M.W. Use of preclinical models to improve treatment of retinoblastoma. PLoS Med. 2005, 2:e332.
12. Fassnacht M., Libe R., Kroiss M., Allolio B. Adrenocortical carcinoma: a clinician's update. Nat. Rev. Endocrinol. 2011, 7:323-335.
13. Ferrari A., Bisogno G., De Salvo G.L., Indolfi P., Perilongo G., Cecchetto G. The challenge of very rare tumours in childhood: the Italian TREP project. Eur. J. Cancer 2007, 43:654-659.
14. Figueiredo B.C., Sandrini R., Zambetti G.P., Pereira R.M., Cheng C., Liu W., et al. Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation. J. Med. Genet. 2006, 43:91-96.
15. Garber J.E., Goldstein A.M., Kantor A.F., Dreyfus M.G., Fraumeni J.F., Li F.P. Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res. 1991, 51:6094-6097.
16. Gonzalez K.D., Noltner K.A., Buzin C.H., Gu D., Wen-Fong C.Y., Nguyen V.Q., et al. Beyond Li-Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J. Clin. Oncol. 2009, 27:1250-1256.
17. Hisada M., Garber J.E., Fung C.Y., Fraumeni J.F., Li F.P. Multiple primary cancers in families with Li-Fraumeni syndrome. J. Natl. Cancer Inst. 1998, 90:606-611.
18. Hovi L., Wikstrom S., Vettenranta K., Heikkila P., Saarinen-Pihkala U.M. Adrenocortical carcinoma in children: a role for etoposide and cisplatin adjuvant therapy? Preliminary report. Med. Pediatr. Oncol. 2003, 40:324-326.
19. Klein J.D., Turner C.G., Gray F.L., Yu D.C., Kozakewich H.P., Perez-Atayde A.R., et al. Adrenal cortical tumors in children: factors associated with poor outcome. J. Pediatr. Surg. 2011, 46:1201-1207.
20. Latronico A.C., Pinto E.M., Domenice S., Fragoso M.C., Martin R.M., Zerbini M.C., et al. An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. J. Clin. Endocrinol. Metab. 2001, 86:4970-4973.
21. Lee J.E., Berger D.H., el-Naggar A.K., Hickey R.C., Vassilopoulou-Sellin R., Gagel R.F., et al. Surgical management, DNA content, and patient survival in adrenal cortical carcinoma. Surgery 1995, 118:1090-1098.
22. Lefevre M., Gerard-Marchant R., Chaussain J.L., et al. Adrenal cortical carcinoma in children: 42 patients treated from 1958 to 1980 at Villejuif. Adrenal and Endocrine Tumors in Children 1983, 265-276. Martinus Nijhoff, Boston, MA. G.B. Humphrey, G.B. Grindey, L.P. Dehner (Eds.).
23. Leung L.Y.J., Leung W.Y., Chan K.F., Fan T.W., Chung K.W., Chan C.H.S. Ruptured adrenocortical carcinoma as a cause of paediatric acute abdomen. Pediatr. Surg. Int. 2002, 730-732.
24. Li F.P., Fraumeni J.F. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?. Ann. Intern. Med. 1969, 71:747-752.
25. Li F.P., Fraumeni J.F., Mulvihill J.J., Blattner W.A., Dreyfus M.G., Tucker M.A., et al. A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988, 48:5358-5362.
26. MacDonald T.J. Aggressive infantile embryonal tumors. J. Child Neurol. 2008, 23:1195-1204.
27. Malkin D., Li F.P., Strong L.C., Fraumeni J.F., Nelson C.E., Kim D.H., et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990, 250:1233-1238.
28. Marigo C., Muller H., Davies J.N.P. Survey of cancer in children admitted to a Brazilian charity hospital. J. Natl. Cancer Inst. 1968, 43:1231-1240.
29. Michalkiewicz E., Sandrini R., Figueiredo B., Miranda E.C., Caran E., Oliveira-Filho A.G., et al. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the international pediatric adrenocortical tumor registry. J. Clin. Oncol. 2004, 22:838-845.
30. Miller R.W. Relation between cancer and congenital defects: an epidemiologic evaluation. J. Natl Cancer Inst. 1968, 40:1079-1085.
31. Miller R.W., Young J.L., Novakovic B. Childhood cancer. Cancer 1995, 75:395-405.
32. Moschovi M., Alexiou G.A., Patereli A., Stefanaki K., Doussis-Anagnostopoulou I., Stofas A., et al. Prognostic significance of cyclin A and B1 in pediatric embryonal tumors. J. Neurooncol. 2010, 103:699-704.
33. Oliveira C.R., Mendonca B.B., Camargo O.P., Pinto E.M., Nascimento S.A., Latorre Mdo R., et al. Classical osteoblastoma, atypical osteoblastoma, and osteosarcoma: a comparative study based on clinical, histological, and biological parameters. Clinics (Sao Paulo) 2007, 62:167-174.
34. Olivier M., Goldgar D.E., Sodha N., Ohgaki H., Kleihues P., Hainaut P., et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res. 2003, 63:6643-6650.
35. Pappo A.S., Krailo M., Chen Z., Rodriguez-Galindo C., Reaman G. Infrequent tumor initiative of the Children's Oncology Group: initial lessons learned and their impact on future plans. J. Clin. Oncol. 2010, 28:5011-5016.
36. Pianovski M.A., Maluf E.M., de Carvalho D.S., Ribeiro R.C., Rodriguez-Galindo C., Boffetta P., et al. Mortality rate of adrenocortical tumors in children under 15 years of age in Curitiba, Brazil. Pediatr. Blood Cancer 2006, 47:56-60.
37. Pinto E.M., Billerbeck A.E., Villares M.C., Domenice S., Mendonca B.B., Latronico A.C. Founder effect for the highly prevalent R337H mutation of tumor suppressor p53 in Brazilian patients with adrenocortical tumors. Arq. Bras. Endocrinol. Metabol. 2004, 48:647-650.
38. Pinto E.M., Ribeiro R.C., Figueiredo B.C., Zambetti G.P. TP53-associated Pediatric Malignancies. Genes & cancer 2011, 2:485-490.
39. Ribeiro R.C., Pinto E.M., Zambetti G.P. Familial predisposition to adrenocortical tumors: clinical and biological features and management strategies. Best Pract. Res. Clin. Endocrinol. Metab. 2010, 24:477-490.
40. Ribeiro R.C., Sandrini Neto R.S., Schell M.J., Lacerda L., Sambaio G.A., Cat I. Adrenocortical carcinoma in children: a study of 40 cases. J. Clin. Oncol. 1990, 8:67-74.
41. Ribeiro R.C., Sandrini F., Figueiredo B., Zambetti G.P., Michalkiewicz E., Lafferty A.R., et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc. Natl Acad. Sci. USA 2001, 98:9330-9335.
42. Ribeiro R.C., Figueiredo B. Childhood adrenocortical tumours. Eur. J. Cancer 2004, 40:1117-1126.
43. Ries, L., Smith, M., Gurney, J. et al., 1999. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. Bethesda, MD, National Cancer Institute, SEER Program Pub. No. 99-4649.
44. Rodriguez-Galindo C., Figueiredo B.C., Zambetti G.P., Ribeiro R.C. Biology, clinical characteristics, and management of adrenocortical tumors in children. Pediatr. Blood Cancer 2005, 45:265-273.
45. Sandrini R., Ribeiro R.C., DeLacerda L. Childhood adrenocortical tumors. J. Clin. Endocrinol. Metab. 1997, 82:2027-2031.
46. Seidinger A.L., Mastellaro M.J., Paschoal Fortes F., Godoy Assumpcao J., Aparecida Cardinalli I., Aparecida Ganazza M., et al. Association of the highly prevalent TP53 R337H mutation with pediatric choroid plexus carcinoma and osteosarcoma in southeast Brazil. Cancer 2010, 117:2228-2235.
47. Stewart J.N., Flageole H., Kavan P. A surgical approach to adrenocortical tumors in children: the mainstay of treatment. J. Pediatr. Surg. 2004, 39:759-763.
48. Stiller C.A., Draper G.J. Treatment centre size, entry to trials, and survival in acute lymphoblastic leukaemia. Arch. Dis. Child. 1989, 64:657-661.
49. Stiller C.A. Aetiology and epidemiology. Paediatric Oncology: Clinical Practice and Controversies 1992, Chapman and Hall Medical. P.N. Plowman, C.R. Pinkerton (Eds.).
50. Tabori U., Malkin D. Risk stratification in cancer predisposition syndromes: lessons learned from novel molecular developments in Li-Fraumeni syndrome. Cancer Res. 2008, 68:2053-2057.
51. Terzolo M., Angeli A., Fassnacht M., Daffara F., Tauchmanova L., Conton P.A., et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N. Engl. J. Med. 2007, 356:2372-2380.
52. Tissier F. Classification of adrenal cortical tumors: what limits for the pathological approach?. Best Pract. Res. Clin. Endocrinol. Metab. 2010, 24:877-885.
53. Tucci S., Martins A.C., Suaid H.J., Cologna A.J., Reis R.B. The impact of tumor stage on prognosis in children with adrenocortical carcinoma. J. Urol. 2005, 174:2338-2342. (Discussion 2342).
54. Varley J.M., McGown G., Thorncroft M., James L.A., Margison G.P., Forster G., et al. Are there low-penetrance TP53 Alleles? Evidence from childhood adrenocortical tumors. Am. J. Hum. Genet. 1999, 65:995-1006.
55. Weiss L.M. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am. J. Surg. Pathol. 1984, 8:163-169.
56. West A.N., Ribeiro R.C., Jenkins J., Rodriguez-Galindo C., Figueiredo B.C., Kriwacki R., et al. Identification of a novel germ line variant hotspot mutant p53-R175L in pediatric adrenal cortical carcinoma. Cancer Res. 2006, 66:5056-5062.
57. Zambetti G.P. The p53 mutation " gradient effect" and its clinical implications. J. Cell. Physiol. 2007, 213:370-373.
58. Zancanella P., Pianovski M.A., Oliveira B.H., Ferman S., Piovezan G.C., Lichtvan L.L., et al. Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression. J. Pediatr. Hematol. Oncol. 2006, 28:513-524.